Skip to main content

Table 4 Relationship between MEG3 rs3087918 and clinical characteristics of cases

From: LncRNA MEG3 rs3087918 was associated with a decreased breast cancer risk in a Chinese population: a case-control study

rs3087918 TT TG GG TG + GG
Age
  > 49/<=49 102/69 120/87 28/19 148/106
 OR(95%CI) 1.00 (reference) 0.93 (0.62–1.408) 1.00 (0.52–1.95) 0.94 (0.64–1.40)
P-value   0.742 0.993 0.777
BMI (kg/m2)
  > =24/< 24 37/134 60/147 12/35 72/182
 OR(95%CI) 1.00 (reference) 1.48 (0.92–2.37) 1.24 (0.59–2.63) 1.43 (0.91–2.26)
P-value   0.104 0.571 0.120
Menstrual status
 yes/no 114/57 128/79 29/18 157/97
 OR(95%CI) 1.00 (reference) 0.81 (0.53–1.24) 0.81 (0.42–1.59) 0.81 (0.54–1.21)
P-value   0.330 0.526 0.307
Tumor size (cm)
  > 2/<=2 85/86 107/100 31/16 138/116
 OR(95%CI) 1.00 (reference) 1.08 (0.72–1.62) 1.96 (1.01–3.92) 1.20 (0.82–1.73)
P-value   0.701 0.050 0.350
Metastasis
 Positive/negtive 93/78 104/103 24/23 128/126
 OR(95%CI) 1.00 (reference) 0.85 (0.56–1.27) 0.88 (0.46–1.68) 0.85 (0.58–1.26)
P-value   0.422 0.686 0.419
Clinical Stage
 III-IV/I-II 51/120 59/148 16/31 75/179
 OR(95%CI) 1.00 (reference) 0.94 (0.60–1.47) 1.21 (0.60–2.39) 0.99 (0.65–1.51)
P-value   0.778 0.579 0.948
ER
 Positive/negtive 115/56 138/69 33/14 171/83
 OR(95%CI) 1.00 (reference) 0.97 (0.63–1.50) 1.15 (0.58–2.37) 1.00 (0.66–1.51)
P-value   0.904 0.700 0.988
PR
 Positive/negtive 94/77 112/95 33/14 145/109
 OR(95%CI) 1.00 (reference) 0.97 (0.64–1.45) 1.93 (0.98–3.97) 1.09 (0.74–1.61)
P-value   0.867 0.063 0.666
Her-2
 Positive/negtive 62/109 90/117 27/20 117/137
 OR(95%CI) 1.00 (reference) 1.35 (0.89–2.05) 2.37 (1.24–4.63) 1.50 (1.01–2.24)
P-value   0.155 0.01* 0.045*
  1. BMI: body mass index, ER: estrogen receptor, PR: progesterone receptor, Her-2: human epidermal growth factor receptor-2, OR: odds ratio, CI: confidence interval
  2. *The P Value < 0.05
\